115 related articles for article (PubMed ID: 19097777)
1. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
Li Y; Liang J; Siu T; Hu E; Rossi MA; Barnett SF; Defeo-Jones D; Jones RE; Robinson RG; Leander K; Huber HE; Mittal S; Cosford N; Prasit P
Bioorg Med Chem Lett; 2009 Feb; 19(3):834-6. PubMed ID: 19097777
[TBL] [Abstract][Full Text] [Related]
2. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.
Siu T; Liang J; Arruda J; Li Y; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4186-90. PubMed ID: 18539456
[TBL] [Abstract][Full Text] [Related]
5. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
Guay D; Boulet L; Friesen RW; Girard M; Hamel P; Huang Z; Laliberté F; Laliberté S; Mancini JA; Muise E; Pon D; Styhler A
Bioorg Med Chem Lett; 2008 Oct; 18(20):5554-8. PubMed ID: 18835163
[TBL] [Abstract][Full Text] [Related]
6. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1807-10. PubMed ID: 19217284
[TBL] [Abstract][Full Text] [Related]
7. 2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Owen DR; Rodriguez-Lens M; Corless MD; Gaulier SM; Horne VA; Kinloch RA; Maw GN; Pearce DW; Rees H; Ringer TJ; Ryckmans T; Stammen BL
Bioorg Med Chem Lett; 2009 Mar; 19(6):1702-6. PubMed ID: 19231185
[TBL] [Abstract][Full Text] [Related]
8. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
[TBL] [Abstract][Full Text] [Related]
9. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781
[TBL] [Abstract][Full Text] [Related]
10. 1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10H-pyrimido[1,2-a][1,8]naphthyridine-6-carboxamide derivative.
Di Braccio M; Grossi G; Alfei S; Ballabeni V; Tognolini M; Flammini L; Giorgio C; Bertoni S; Barocelli E
Eur J Med Chem; 2014 Oct; 86():394-405. PubMed ID: 25194932
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
Sasaki T; Takahashi T; Nagase T; Mizutani T; Ito S; Mitobe Y; Miyamoto Y; Kanesaka M; Yoshimoto R; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4232-6. PubMed ID: 19520574
[TBL] [Abstract][Full Text] [Related]
12. 3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.
Scott DA; Bell KJ; Campbell CT; Cook DJ; Dakin LA; Del Valle DJ; Drew L; Gero TW; Hattersley MM; Omer CA; Tyurin B; Zheng X
Bioorg Med Chem Lett; 2009 Feb; 19(3):701-5. PubMed ID: 19114305
[TBL] [Abstract][Full Text] [Related]
13. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
Hartnett JC; Barnett SF; Bilodeau MT; Defeo-Jones D; Hartman GD; Huber HE; Jones RE; Kral AM; Robinson RG; Wu Z
Bioorg Med Chem Lett; 2008 Mar; 18(6):2194-7. PubMed ID: 18294842
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine.
Yoshizumi T; Miyazoe H; Ito H; Tsujita T; Takahashi H; Asai M; Ozaki S; Ohta H; Okamoto O
Bioorg Med Chem Lett; 2008 Jul; 18(13):3778-82. PubMed ID: 18515099
[TBL] [Abstract][Full Text] [Related]
15. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.
Zhao Z; Leister WH; Robinson RG; Barnett SF; Defeo-Jones D; Jones RE; Hartman GD; Huff JR; Huber HE; Duggan ME; Lindsley CW
Bioorg Med Chem Lett; 2005 Feb; 15(4):905-9. PubMed ID: 15686884
[TBL] [Abstract][Full Text] [Related]
17. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.
Lindsley CW; Zhao Z; Leister WH; Robinson RG; Barnett SF; Defeo-Jones D; Jones RE; Hartman GD; Huff JR; Huber HE; Duggan ME
Bioorg Med Chem Lett; 2005 Feb; 15(3):761-4. PubMed ID: 15664853
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
Lin X; Murray JM; Rico AC; Wang MX; Chu DT; Zhou Y; Del Rosario M; Kaufman S; Ma S; Fang E; Crawford K; Jefferson AB
Bioorg Med Chem Lett; 2006 Aug; 16(16):4163-8. PubMed ID: 16765046
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Becknell NC; Dandu RR; Lyons JA; Aimone LD; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(1):186-9. PubMed ID: 22153342
[TBL] [Abstract][Full Text] [Related]
20. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]